Pfenex Stock Price - PFNX

Best deals to access real time data!
Big Cap Pro
Monthly Subscription
for only
Small Cap Pro
Monthly Subscription
for only
DDE w/Realtime (Monthly)
Monthly Subscription
for only
VAT not included
After Hours
Last Trade
Last $ 12.30 ◊ 0.00 (0.00%)
Company Name Stock Ticker Symbol Market Type
Pfenex Inc PFNX AMEX Common Stock
  Price Change Change Percent Stock Price High Price Low Price Open Price Close Price Last Traded
  -0.22 -1.76% 12.30 12.80 12.09 12.79 12.52 23:59:44
Stock Trades Traded Volume VWAP Dollar Volume Average Volume 52 Week Range
3,023 373,608 $ 12.43 $ 4,642,398 348,105 3.40 - 13.95
Last Trade Time Type Quantity Stock Price Currency
19:59:37 13,818 $ 12.30 USD

Pfenex Financials

Market Cap Shares in Issue Profit/Loss Earnings Per Share (EPS) PE Ratio Float
$ 389.61M 31.68M $ -39.59M -1.42 -90.80 30.90M
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
535.75k $ - 0.00% - -

more financials information »

Pfenex News

Loading Messages....

Latest PFNX Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical PFNX Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week12.4413.9512.0912.86357,718-0.14-1.13%
1 Month12.3913.9510.5412.19331,545-0.09-0.73%
3 Months9.7413.958.41311.18296,1102.5626.28%
6 Months5.9313.955.609.56298,5356.37107.42%
1 Year3.9013.953.408.32234,9648.40215.38%
3 Years9.0313.952.076.35172,3883.2736.21%
5 Years6.7824.412.078.51146,5815.5281.42%

Pfenex Description

Pfenex Inc is a clinical-stage biotechnology company involved in the development of protein production and bioanalytic technology. The biosimilars portfolio include PF582, for the treatment of patients with retinal diseases; PF530, designed to treat patients with multiple sclerosis; and PF708, to treat osteoporosis patients at high risk of fractures. Its vaccine portfolio consists of Px563L, a novel anthrax vaccine candidate to meet U.S. government demand, funded by the U.S. Department of Health and Human Services, through the Biomedical Advanced Research and Development Authority.

Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.